326 reports of this reaction
4.7% of all ATAZANAVIR SULFATE reports
#4 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #4 most commonly reported adverse reaction for ATAZANAVIR SULFATE, manufactured by Aurobindo Pharma Limited. There are 326 FDA adverse event reports linking ATAZANAVIR SULFATE to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 4.7% of all 6,992 adverse event reports for this drug.
Patients taking ATAZANAVIR SULFATE who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among ATAZANAVIR SULFATE users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for ATAZANAVIR SULFATE:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 326 FDA reports for ATAZANAVIR SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 4.7% of all adverse event reports for ATAZANAVIR SULFATE, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking ATAZANAVIR SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.